Watch this 15 minute AHA Recap for thromboembolic disease! ➡️ http://ms.spr.ly/6183oXAP7 Geoffrey D. Barnes, MD reviews the ONCO PE Trial as presented at AHA, finding that if you can tolerate an anticoagulant, then extended courses of rivaroxaban, for treating cancer-associated venous thromboembolism, tend to not increase bleeding over the long term, but have huge benefits in preventing recurrent PE. | Theheart.org/Medscape Cardiology